A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
NCT06541847
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
25
Enrollment
INDUSTRY
Sponsor class
Conditions
Neurofibromatosis Type 1
Interventions
DRUG:
HLX-1502
Sponsor
Healx Limited